Continuous immunosensing of myoglobin in human serum as potential companion diagnostics technique

Dong Hyung Kim, Sung Min Seo, Hyun Mo Cho, Sun June Hong, Do-Sun Lim, Se Hwan Paek

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

To attain early diagnosis of acute myocardial infarction (AMI) with enhanced accuracy, continuous immunosensing has been investigated to measure myoglobin concentration in real-time. To this end, a capture antibody showing rapid reaction kinetics was immobilized on the surface of a surface plasmon resonance sensor. Three problems associated with the continuous sensing of myoglobin in human serum needed to be overcome: non-specific binding of the analyte, aggregation of serum components, and drift of the sensor baseline. Non-specific binding was controlled by pretreating the sample with a detergent mixture consisting of sodium dodecyl sulfate and P20, and adjusting the micelle size and net charge. Aggregation was managed by inactivating certain serum constituents through chelation of heavy metals. Baseline drift perceived in the sensorgram was able to be corrected by compensating for the slope calculated by a linear regression. Under the optimal conditions, the continuous sensor reproducibly traced the varying doses of myoglobin over about 8h with periodic one-point calibration every 3h. The dose-response curve of the sensor was linear with acceptable variations (CVs<4.91% in average) between the detection limit (31.0ng/mL) and about 2000ng/mL in the arithmetic scale (R2>0.98), covering the clinical concentration range. The immunosensor performance correlated with the Pathfast reference system (R2>0.98) and analytical consistency could be maintained for longer than a month if appropriately calibrated. Such immunosensing could be used as a companion diagnostic means along with real-time electrocardiographic measurement, significantly enhancing the sensitivity of AMI diagnosis and thereby enabling treatment at an early stage.

Original languageEnglish
Pages (from-to)234-241
Number of pages8
JournalBiosensors and Bioelectronics
Volume62
DOIs
Publication statusPublished - 2014 Dec 15

Fingerprint

Myoglobin
Sensors
Serum
Myocardial Infarction
Agglomeration
Surface Plasmon Resonance
Micelles
Heavy Metals
Immunosensors
Sodium Dodecyl Sulfate
Detergents
Calibration
Early Diagnosis
Linear Models
Sodium dodecyl sulfate
Surface plasmon resonance
Chelation
Time measurement
Linear regression
Antibodies

ASJC Scopus subject areas

  • Biophysics
  • Biomedical Engineering
  • Biotechnology
  • Electrochemistry

Cite this

Continuous immunosensing of myoglobin in human serum as potential companion diagnostics technique. / Kim, Dong Hyung; Seo, Sung Min; Cho, Hyun Mo; Hong, Sun June; Lim, Do-Sun; Paek, Se Hwan.

In: Biosensors and Bioelectronics, Vol. 62, 15.12.2014, p. 234-241.

Research output: Contribution to journalArticle

Kim, Dong Hyung ; Seo, Sung Min ; Cho, Hyun Mo ; Hong, Sun June ; Lim, Do-Sun ; Paek, Se Hwan. / Continuous immunosensing of myoglobin in human serum as potential companion diagnostics technique. In: Biosensors and Bioelectronics. 2014 ; Vol. 62. pp. 234-241.
@article{e630c3e2d5fc4f75818acda6c4736630,
title = "Continuous immunosensing of myoglobin in human serum as potential companion diagnostics technique",
abstract = "To attain early diagnosis of acute myocardial infarction (AMI) with enhanced accuracy, continuous immunosensing has been investigated to measure myoglobin concentration in real-time. To this end, a capture antibody showing rapid reaction kinetics was immobilized on the surface of a surface plasmon resonance sensor. Three problems associated with the continuous sensing of myoglobin in human serum needed to be overcome: non-specific binding of the analyte, aggregation of serum components, and drift of the sensor baseline. Non-specific binding was controlled by pretreating the sample with a detergent mixture consisting of sodium dodecyl sulfate and P20, and adjusting the micelle size and net charge. Aggregation was managed by inactivating certain serum constituents through chelation of heavy metals. Baseline drift perceived in the sensorgram was able to be corrected by compensating for the slope calculated by a linear regression. Under the optimal conditions, the continuous sensor reproducibly traced the varying doses of myoglobin over about 8h with periodic one-point calibration every 3h. The dose-response curve of the sensor was linear with acceptable variations (CVs<4.91{\%} in average) between the detection limit (31.0ng/mL) and about 2000ng/mL in the arithmetic scale (R2>0.98), covering the clinical concentration range. The immunosensor performance correlated with the Pathfast reference system (R2>0.98) and analytical consistency could be maintained for longer than a month if appropriately calibrated. Such immunosensing could be used as a companion diagnostic means along with real-time electrocardiographic measurement, significantly enhancing the sensitivity of AMI diagnosis and thereby enabling treatment at an early stage.",
keywords = "Anti-serum aggregation, Baseline drift correction, Clinical sample pretreatment, Continuous immunosensor, Immunosensing performances",
author = "Kim, {Dong Hyung} and Seo, {Sung Min} and Cho, {Hyun Mo} and Hong, {Sun June} and Do-Sun Lim and Paek, {Se Hwan}",
year = "2014",
month = "12",
day = "15",
doi = "10.1016/j.bios.2014.06.039",
language = "English",
volume = "62",
pages = "234--241",
journal = "Biosensors",
issn = "0956-5663",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Continuous immunosensing of myoglobin in human serum as potential companion diagnostics technique

AU - Kim, Dong Hyung

AU - Seo, Sung Min

AU - Cho, Hyun Mo

AU - Hong, Sun June

AU - Lim, Do-Sun

AU - Paek, Se Hwan

PY - 2014/12/15

Y1 - 2014/12/15

N2 - To attain early diagnosis of acute myocardial infarction (AMI) with enhanced accuracy, continuous immunosensing has been investigated to measure myoglobin concentration in real-time. To this end, a capture antibody showing rapid reaction kinetics was immobilized on the surface of a surface plasmon resonance sensor. Three problems associated with the continuous sensing of myoglobin in human serum needed to be overcome: non-specific binding of the analyte, aggregation of serum components, and drift of the sensor baseline. Non-specific binding was controlled by pretreating the sample with a detergent mixture consisting of sodium dodecyl sulfate and P20, and adjusting the micelle size and net charge. Aggregation was managed by inactivating certain serum constituents through chelation of heavy metals. Baseline drift perceived in the sensorgram was able to be corrected by compensating for the slope calculated by a linear regression. Under the optimal conditions, the continuous sensor reproducibly traced the varying doses of myoglobin over about 8h with periodic one-point calibration every 3h. The dose-response curve of the sensor was linear with acceptable variations (CVs<4.91% in average) between the detection limit (31.0ng/mL) and about 2000ng/mL in the arithmetic scale (R2>0.98), covering the clinical concentration range. The immunosensor performance correlated with the Pathfast reference system (R2>0.98) and analytical consistency could be maintained for longer than a month if appropriately calibrated. Such immunosensing could be used as a companion diagnostic means along with real-time electrocardiographic measurement, significantly enhancing the sensitivity of AMI diagnosis and thereby enabling treatment at an early stage.

AB - To attain early diagnosis of acute myocardial infarction (AMI) with enhanced accuracy, continuous immunosensing has been investigated to measure myoglobin concentration in real-time. To this end, a capture antibody showing rapid reaction kinetics was immobilized on the surface of a surface plasmon resonance sensor. Three problems associated with the continuous sensing of myoglobin in human serum needed to be overcome: non-specific binding of the analyte, aggregation of serum components, and drift of the sensor baseline. Non-specific binding was controlled by pretreating the sample with a detergent mixture consisting of sodium dodecyl sulfate and P20, and adjusting the micelle size and net charge. Aggregation was managed by inactivating certain serum constituents through chelation of heavy metals. Baseline drift perceived in the sensorgram was able to be corrected by compensating for the slope calculated by a linear regression. Under the optimal conditions, the continuous sensor reproducibly traced the varying doses of myoglobin over about 8h with periodic one-point calibration every 3h. The dose-response curve of the sensor was linear with acceptable variations (CVs<4.91% in average) between the detection limit (31.0ng/mL) and about 2000ng/mL in the arithmetic scale (R2>0.98), covering the clinical concentration range. The immunosensor performance correlated with the Pathfast reference system (R2>0.98) and analytical consistency could be maintained for longer than a month if appropriately calibrated. Such immunosensing could be used as a companion diagnostic means along with real-time electrocardiographic measurement, significantly enhancing the sensitivity of AMI diagnosis and thereby enabling treatment at an early stage.

KW - Anti-serum aggregation

KW - Baseline drift correction

KW - Clinical sample pretreatment

KW - Continuous immunosensor

KW - Immunosensing performances

UR - http://www.scopus.com/inward/record.url?scp=84904063906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904063906&partnerID=8YFLogxK

U2 - 10.1016/j.bios.2014.06.039

DO - 10.1016/j.bios.2014.06.039

M3 - Article

C2 - 25016254

AN - SCOPUS:84904063906

VL - 62

SP - 234

EP - 241

JO - Biosensors

JF - Biosensors

SN - 0956-5663

ER -